Improving the anticancer effect of afatinib and microRNA by using lipid polymeric nanoparticles conjugated with dual pH-responsive and targeting peptides

Table 1 Characterization of afatinib or miR-139 in various LPNs

Formulations	Particle size (nm)	PDI	Zeta potential (mV)	EE (%)	DL (%)
Afa/LPN	175.5 ± 1.5	0.11 ± 0.04	− 13.1 ± 1.6	87.5 ± 1.7	15.4 ± 1.2
Afa/LPN-H	176.1 ± 2.0	0.12 ± 0.04	− 14.4 ± 1.0	–
Afa/LPN-R	162.1 ± 1.8	0.13 ± 0.17	− 14.2 ± 1.3	–
Afa/LPN-HR at pH 7.4	147.3 ± 2.3	0.21 ± 0.01	− 10.2 ± 1.4	87.3 ± 1.3	15.3 ± 1.6
Afa/LPN-HR at pH 6.5	183.8 ± 1.0	0.22 ± 0.01	− 5.7 ± 0.9	–
miR-139/LPN-HR at pH 7.4	141.2 ± 3.1	0.19 ± 0.11	− 15.2 ± 1.4	86.2 ± 1.8	16.2 ± 0.9
miR-139/LPN-HR at pH 6.5	175.6 ± 2.6	0.22 ± 0.14	− 11.7 ± 1.2	–

Particle size, PDI and zeta potential of Afa or miR-139 in various LPNs were measured by zetasizer. EE % of Afa in LPN or LPN-HR and miR-139 in LPN-HR was calculated after detection of Afa or miR-139 by HPLC–UV and microplate reader, respectively
Afa afatinib, PDI polydispersity index, EE encapsulation efficiency, DL drug loading capacity

ISSN: 1477-3155